Gemtesa (vibegron) is a prescription medication used to treat overactive bladder (OAB) in adults. It was approved by the FDA in 2020 for people experiencing the hallmark symptoms of OAB: a sudden, hard-to-control urge to urinate, frequent bathroom trips, and leaking urine before you can reach a toilet. In 2024, the FDA expanded its approval to also cover OAB symptoms in men who are already taking medication for an enlarged prostate.
How Gemtesa Works
Gemtesa belongs to a class of drugs called beta-3 adrenergic agonists. In simple terms, it activates specific receptors on the bladder muscle that help it relax during the filling phase, when your bladder is storing urine between bathroom trips. When those receptors are stimulated, the bladder is less likely to contract involuntarily, which is what causes that sudden “gotta go” feeling.
The mechanism is more nuanced than just relaxing the muscle directly. At therapeutic doses, Gemtesa also appears to quiet nerve signaling in the bladder wall. It reduces the release of a chemical messenger (acetylcholine) from nerves that would otherwise trigger the bladder to squeeze, and it suppresses the small spontaneous contractions that can create a false sense of urgency. These combined effects mean fewer sudden urges and more time between bathroom visits.
What the Clinical Trials Showed
In a 12-week study involving over 900 participants, people taking Gemtesa experienced about 2 fewer daily leakage episodes, compared to roughly 1.4 fewer for those on a placebo. Bathroom visits dropped by nearly 2 per day with Gemtesa versus about 1.3 fewer with placebo. The urgency-driven trips (the ones where you feel you absolutely cannot wait) decreased by about 2.7 per day, compared to 2 fewer for placebo.
Those differences may sound modest on paper, but for someone making 10 or more urgent bathroom trips a day, cutting nearly 2 of those and reducing leakage episodes can meaningfully change daily life. It can mean fewer interruptions at work, better sleep, and more confidence leaving the house.
How It Compares to Older OAB Medications
For decades, the standard medications for overactive bladder were anticholinergics (drugs like oxybutynin, tolterodine, and solifenacin). These work by blocking the nerve signals that make the bladder contract, but they also block those same signals throughout the body. That leads to familiar side effects: dry mouth, constipation, blurred vision, and in older adults, growing concerns about cognitive effects with long-term use.
Gemtesa works through an entirely different pathway. Because it activates beta-3 receptors rather than blocking acetylcholine receptors, it does not cause dry mouth or constipation. This is a significant practical advantage, since dry mouth and constipation are the top reasons people stop taking traditional OAB drugs. The American Urological Association now advises that beta-3 agonists like Gemtesa are typically preferred before trying anticholinergic medications. That recommendation carries the organization’s strongest evidence rating.
Common Side Effects
Gemtesa’s side effect profile is relatively mild. In the 12-week clinical trial, the most commonly reported side effects (occurring in at least 2% of patients and more often than placebo) were headache (4% vs. 2.4% with placebo) and nasopharyngitis, essentially a common cold (2.8% vs. 1.7%). In a longer-term study lasting up to a year, urinary tract infections (6.6%) and bronchitis (2.9%) were also reported, though UTIs are common in the OAB population generally.
One interaction worth knowing about: if you take digoxin (a heart medication), Gemtesa can increase digoxin levels in your blood by roughly 10 to 20%. Your doctor will likely check digoxin levels before starting Gemtesa and may adjust your dose.
What Taking Gemtesa Looks Like
Gemtesa is taken as a single 75 mg tablet once daily, with or without food. For people who have difficulty swallowing pills, the tablet can be crushed and mixed with a spoonful of applesauce, then taken immediately. There’s no need to ramp up the dose gradually or take multiple pills throughout the day.
Most people in the clinical trials began noticing improvements within the first few weeks, with the full effect measured at the 12-week mark. It’s not a medication that works instantly on the first dose, so it requires some patience.
Cost and Savings Programs
As a brand-name medication without a generic equivalent, Gemtesa can be expensive out of pocket. The manufacturer offers a Simple Savings Program for people with commercial insurance. If your plan covers Gemtesa, you may pay as little as $0 for a 90-day supply or $10 for a 30-day supply. Even if your commercial plan doesn’t cover it, the card can bring the cost down to around $95 for a 30-day supply.
The savings card is valid for up to 12 fills of a 30-day supply (or 4 fills of a 90-day supply) and expires one year after activation. You can enroll online or text “GEMTESA” to 636872 for a digital card. People on Medicare, Medicaid, or other government insurance programs are not eligible for the commercial savings card but may qualify for the Sumitomo Patient Assistance Program by calling 833-876-8268.